1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Zoetis Inc.

Zoetis Inc.

ZTS
Zoetis Inc.US flagNew York Stock Exchange
79.57
USD
-1.83
- -
33.36BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.12
9.55
9.54
9.86
10.83
12.06
13.09
14.04
16.39
17.23
18.53
20.38
21.35
21.76
Basic EPS, GAAP
1.01
1.16
0.68
1.66
1.76
2.96
3.14
3.44
4.29
4.51
5.08
5.47
6.03
6.05
Free Cash Flow per Basic Share
0.99
0.86
0.88
1
2.75
3.71
3.75
4.47
4.67
4.08
5.1
6.5
6.55
6.38
Dividend per Share
0.2
0.29
0.34
0.38
0.42
0.5
0.66
0.8
1
1.3
1.5
1.73
2
2.03
Book Value per Share
0.56
1.42
1.76
2.99
4.32
6.78
9.27
11.91
15.16
18.5
22.33
26.36
31.01
32.46
Tangible Book Value per Share
-1.65
-0.73
-3.11
-2.44
-2.03
-4.93
-3.71
-1.33
0.82
0.59
1.94
2.02
-0.98
-1.15
Basic Weighted Avg Shares
500
501
500
496
490
483
478
476
474
469
461
454
443
437
Sales/Revenue/Turnover
4,561
4,785
4,765
4,888
5,307
5,825
6,260
6,675
7,776
8,080
8,544
9,256
9,467
9,509
Operating Margin (%)
17.98
20.25
22.46
28.58
32.5
32.29
32.24
33.99
36.05
36.24
35.92
36.65
38
37.57
Depreciation Expense
209
204
199
240
242
308
412
441
448
465
491
497
487
487
Net Income, GAAP
504
583
339
821
864
1,428
1,500
1,638
2,037
2,114
2,344
2,486
2,673
2,643
Effective Tax Rate (%)
27.1
28.41
37.8
33.31
43.48
15.74
16.71
18.04
18.25
20.52
20.3
20.33
20.45
20.1
Profit Margin (%)
11.05
12.18
7.11
16.8
16.28
24.52
23.96
24.54
26.2
26.16
27.43
26.86
28.23
27.79
Working Capital
1,942
2,379
2,049
2,273
3,123
3,176
2,942
4,441
5,133
4,339
4,454
2,574
4,533
4,421
LT Debt
3,642
3,624
4,463
4,468
4,953
6,443
6,111
6,758
6,743
6,738
6,752
5,394
9,238
9,238
Total Equity
962
1,337
1,091
1,499
1,786
2,185
2,708
3,773
4,544
4,403
4,991
4,770
3,331
3,233
Return on Invested Capital (%)
12.95
14.47
12.16
15.53
15.26
20.55
18.69
18.15
20.4
19.44
19.99
23.07
23.56
23.53
Return on Capital (%)
25.78
15.91
8.21
15.91
14.79
19.1
16.23
15.2
16.49
14.94
15.02
14.85
13.67
13.28
Return on Common Equity (%)
358.72
117.19
42.51
69.49
48.05
53
38.93
32.45
31.69
26.65
24.71
22.32
20.78
19.9

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
7,069
9,042
9,045
LT Finance Leases
204
196
193
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
441
425
420
Market Capitalization
65,336
55,795
51,667

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6,583
6,768
6,474
Cash, Cash Equivalents & STI
2,080
2,310
1,940
Accounts Receivable, Net
1,541
1,590
1,506
Inventories
2,465
2,430
2,550
Total Current Liabilities
1,807
2,235
2,053
Payables & Accruals
1,371
1,718
1,693
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.82%
-0.78%
-30.17%
Free Cash Flow
27.29%
7.48%
-1.66%
Net Income, GAAP
27.95%
10.52%
7.52%
Sales/Revenue/Turnover
7.18%
7.35%
2.28%
Total Cash Common Dividend
18.32%
18.72%
13.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,190
2,361
2,388
2,317
9,256
2025
2,198
2,460
2,400
2,387
9,467
2026
2,262
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.31
1.37
1.51
1.29
5.47
2025
1.34
1.61
1.63
1.38
6.03
2026
1.42
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.43
0.43
0.43
0.43
1.73
2025
0.5
0.5
0.5
0.5
2
2026
0.53
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
Kristin C. Peck
Full Time Employees
13,800
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
10 Sylvan Way Parsippany NJ United States of America 07054
IPO Date
Feb 1, 2013
CIK
0001555280
Website
zoetis.com
Similar Companies
Orion Oyj (ORINY)
Yung Zip Chemical Ind. Co., Ltd. (4102.TWO)
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
Johnson & Johnson (JNJ.DE)
Pfizer Inc. (PFE.F)
Santen Pharmaceutical Co., Ltd. (4536.T)
Business
Zoetis Inc. (NYSE: ZTS) develops, manufactures and commercializes animal health medicines and vaccines, as well as a range of other animal health products and services. The company offers pharmaceuticals including anti-infectives, dermatology products, pain and sedation therapeutics, and reproductive controls; vaccines for livestock and companion animals such as dogs, cats, horses and cattle; and diagnostics, parasiticides, dermatology treatments, medicated topicals, vaccines and therapeutics for small and large animals. Zoetis provides platform technologies like the Zoetis Petcare solutions for pet owners and veterinarians, including telehealth services and data-driven insights, along with contract manufacturing and research services for biopharmaceuticals. Operating in over 100 countries with a primary focus on North America, Europe, and emerging markets in Latin America, Asia and Africa, the company targets veterinarians, livestock producers and pet owners as key customers. Founded in 2012 as a spin-off from Pfizer Inc.'s animal health business and headquartered in Parsippany, New Jersey, Zoetis has no major parent company or significant subsidiaries beyond its global operating units. In recent developments, Zoetis expanded its portfolio through the 2024 launch of new monoclonal antibody therapies for canine osteoarthritis and atopic dermatitis under the Libertym brand, formed a strategic alliance with Pharmgate Animal Health in 2025 for U.S. swine feed antibiotics distribution, and completed the acquisition of Basepaws in 2023 to bolster its pet genetics and diagnostics capabilities, reflecting ongoing innovation and market penetration efforts.

Company News

MCPAPIChat

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • globenewswire.com

    ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

  • zacks.com

    Zoetis (ZTS) Stock Dips While Market Gains: Key Facts

  • prnewswire.com

    Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

  • globenewswire.com

    ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

  • globenewswire.com

    ZTS Shareholder Alert: Zoetis Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

  • globenewswire.com

    Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors that a Class Action Lawsuit Has Been Filed Against Zoetis and Encourages Investors to Contact the Firm Before the July 27th Deadline

  • globenewswire.com

    ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • newsfilecorp.com

    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • prnewswire.com

    Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

  • gurufocus.com

    Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

  • prnewswire.com

    Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

  • prnewswire.com

    ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • prnewswire.com

    ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit

  • globenewswire.com

    ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

  • globenewswire.com

    ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - RGRD Law

  • globenewswire.com

    Portnoy Law Firm Announces Class Action on Behalf of Zoetis, Inc. Investors

  • globenewswire.com

    ZOETIS INC. INVESTORS WITH LOSSES HAVE UNTIL JULY 27, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

  • prnewswire.com

    ZTS Deadline Alert: Levi & Korsinsky Reminds Zoetis Inc. (ZTS) Investors of Securities Class Action Deadline on July 27, 2026